(Q37046564)

17 August 2017

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents (English)

1 reference

17 August 2017

15

Hagop Kantarjian

1 reference

17 August 2017

13

Zeev Estrov

1 reference

17 August 2017

12

Jorge Cortes

1 reference

17 August 2017

7

Tapan Kadia

1 reference

17 August 2017

6

Elias Jabbour

1 reference

17 August 2017

Guillermo Garcia-Manero

series ordinal

16

object named as

Guillermo Garcia-Manero

1 reference

17 August 2017

9

Marina Konopleva

1 reference

17 August 2017

14

Andrew Futreal

1 reference

17 August 2017

10

Courtney DiNardo

1 reference

17 August 2017

11

Naval Daver

1 reference

17 August 2017

3

Carlos Bueso-Ramos

1 reference

17 August 2017

5

Curtis Gumbs

1 reference

17 August 2017

1

Koichi Takahashi

1 reference

17 August 2017

2

Keyur Patel

1 reference

17 August 2017

Jianhua Zhang

4

1 reference

17 August 2017

Michael Andreff

series ordinal

8

1 reference

17 August 2017

language of work or name

English

0 references

publication date

9 February 2016

1 reference

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

12

1 reference

17 August 2017

14172-14187

1 reference

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Clinical and biological implications of driver mutations in myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Revised international prognostic scoring system for myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Clinical effect of point mutations in myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Shaping genetic alterations in human cancer: the p53 mutation paradigm

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

p53 alterations in human cancer: more questions than answers.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Proposals for the classification of the myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924706

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26871476

12 December 2020

inferred from PubMed ID database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26871476

12 December 2020

inferred from PubMed ID database lookup

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26871476

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.18632/ONCOTARGET.7290

1 reference

release_77l7ih76uzbbrobowsljnviwku

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/77l7ih76uzbbrobowsljnviwku

24 November 2022

mapped directly with Wikidata item

1 reference

17 August 2017

PubMed publication ID

26871476

1 reference